BR0209689A - Uso de fragmento de hmg como agente anti-inflamatório - Google Patents

Uso de fragmento de hmg como agente anti-inflamatório

Info

Publication number: BR0209689A
Authority: BR; Brazil
Prior art keywords: hmg; inflammatory agent; vertebrate; fragment; inhibiting
Prior art date: 2001-05-15

Application number

BR0209689-7A

Other languages

English (en)

Portuguese (pt)

Inventor

Kevin J Tracey

Huan Yang

Howland Shaw Warren Jr

Mitchell P Fink

Original Assignee

Long Island Jewish Res Inst

Gen Hospital Corp

Univ Pittsburgh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-05-15

Filing date

2002-05-15

Publication date

2006-02-07

2002-05-15 Application filed by Long Island Jewish Res Inst, Gen Hospital Corp, Univ Pittsburgh filed Critical Long Island Jewish Res Inst

2006-02-07 Publication of BR0209689A publication Critical patent/BR0209689A/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Diabetes (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Pulmonology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Toxicology (AREA)
Tropical Medicine & Parasitology (AREA)
Urology & Nephrology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Hematology (AREA)
Zoology (AREA)
Endocrinology (AREA)
Biotechnology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Cardiology (AREA)

BR0209689-7A 2001-05-15 2002-05-15 Uso de fragmento de hmg como agente anti-inflamatório BR0209689A (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US29103401P	2001-05-15	2001-05-15
PCT/US2002/015329 WO2002092004A2 (en)	2001-05-15	2002-05-15	Use of hmg fragment as anti-inflammatory agents

Publications (1)

Publication Number	Publication Date
BR0209689A true BR0209689A (pt)	2006-02-07

Family

ID=23118552

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BR0209689-7A BR0209689A (pt)	2001-05-15	2002-05-15	Uso de fragmento de hmg como agente anti-inflamatório

Country Status (18)

Country	Link
US (2)	US20030060410A1 (is)
EP (1)	EP1392844A4 (is)
JP (1)	JP2005512507A (is)
KR (1)	KR20040018370A (is)
CN (1)	CN100447154C (is)
AU (1)	AU2002309829B2 (is)
BR (1)	BR0209689A (is)
CA (1)	CA2447576C (is)
CZ (1)	CZ20033402A3 (is)
HU (1)	HUP0500042A3 (is)
IL (3)	IL158643A0 (is)
IS (1)	IS7037A (is)
MX (1)	MXPA03010449A (is)
NO (1)	NO20035087L (is)
NZ (1)	NZ529423A (is)
PL (1)	PL367132A1 (is)
SK (1)	SK15422003A3 (is)
WO (1)	WO2002092004A2 (is)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6303321B1 (en)	1999-02-11	2001-10-16	North Shore-Long Island Jewish Research Institute	Methods for diagnosing sepsis
US7151082B2 (en)	1999-02-11	2006-12-19	The Feinstein Institute For Medical Research	Antagonists of HMG1 for treating inflammatory conditions
ITMI20010562A1 (it) *	2001-03-16	2002-09-16	Marco E Bianchi	Inibitori o antagonisti della proteina hmg1 per il trattamento di disordini vascolari
US7220723B2 (en) *	2001-05-15	2007-05-22	The Feinstein Institute For Medical Research	Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
US7304034B2 (en)	2001-05-15	2007-12-04	The Feinstein Institute For Medical Research	Use of HMGB fragments as anti-inflammatory agents
DE60326453D1 (de) *	2002-07-03	2009-04-16	Ct Cardiologico Monzino S P A	Die verwendung von hmgb1 zur behandlung von gewebeverletzungen und/oder zur unterstützung der gewebewiederherstellung
US20040156851A1 (en) *	2002-11-20	2004-08-12	Critical Therapeutics, Inc.	HMGB1 combination therapies
US20040141948A1 (en) *	2002-11-20	2004-07-22	Critical Therapeutics, Inc.	Use of HMGB fragments as anti-inflammatory agents
EP1567544A4 (en) *	2002-11-20	2009-07-22	Long Island Jewish Res Inst	USE OF HMGB POLYPEPTIDES TO IMPROVE THE IMMUNE REACTIONS
ATE378048T1 (de) *	2002-12-06	2007-11-15	The Feinstein Inst Medical Res	Hemmung von entzündungen unter verwendungvon alpha-7-rezeptor verbindenden cholinergen agonisten
US20090069227A9 (en) *	2003-04-29	2009-03-12	Capogrossi Maurizio C	Use of HMGB1 to promote stem cell migration and/or proliferation
US7696169B2 (en) *	2003-06-06	2010-04-13	The Feinstein Institute For Medical Research	Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
WO2005025604A2 (en) *	2003-09-10	2005-03-24	The General Hospital Corporation	Use of hmgb and hmgb fragments to decrease specific immune response
EP1668035A2 (en)	2003-09-11	2006-06-14	Critical Therapeutics, Inc.	Monoclonal antibodies against hmgb1
EP1768698A4 (en)	2004-06-17	2009-01-28	Medimmune Inc	IMMUNOGENIC COMPOSITIONS COMPRISING HMGB1 POLYPEPTIDES
EP1771565B1 (en)	2004-07-20	2012-09-05	The Feinstein Institute for Medical Research	Rage protein derivatives
US20080075728A1 (en) *	2004-07-20	2008-03-27	Walter Newman	Combination Therapies Of Hmgb And Complement Inhibitors Against Inflammation
WO2006024547A2 (en) *	2004-09-03	2006-03-09	Creabilis Therapeutics S.P.A.	Protease resistant human and non-human hmgb1 box-a mutants and their therapeutic/diagnostic use
US8129130B2 (en)	2004-10-22	2012-03-06	The Feinstein Institute For Medical Research	High affinity antibodies against HMGB1 and methods of use thereof
CN102731654A (zh) *	2004-10-22	2012-10-17	米迪缪尼有限公司	抗hmgb1的高亲和力抗体及其用法
US8354106B2 (en)	2005-06-16	2013-01-15	The Feinstein Institute For Medical Research	Antibodies against HMGB1 and fragments thereof
US20100040608A1 (en) *	2005-07-18	2010-02-18	Marie Wahren-Herlenius	Use of HMGB1 antagonists for the treatment of inflammatory skin conditions
JP3876325B1 (ja) *	2005-10-24	2007-01-31	国立大学法人岡山大学	脳梗塞抑制剤
US20100172909A1 (en) *	2005-10-24	2010-07-08	Masahiro Nishibori	Cerebral edema suppressant
CA2631212A1 (en) *	2005-11-28	2007-07-05	Medimmune, Llc	Antagonists of hmgb1 and/or rage and methods of use thereof
WO2007130725A2 (en) *	2006-02-06	2007-11-15	University Of Pittsburgh Of The Commonwealth System Of Higher Education	Use of hmgb1 for protection against ischemia reperfusion injury
WO2007102410A1 (ja) *	2006-02-24	2007-09-13	National University Corporation Kanazawa University	Rageポリペプチドの新規用途
JP3882090B1 (ja)	2006-05-19	2007-02-14	国立大学法人岡山大学	脳血管攣縮抑制剤
SI2068935T1 (sl) *	2006-09-15	2011-07-29	Creabilis Therapeutics S R L	Polimerni konjugati od Box-A od HMGB1 in Box-A variante od HMGB1
AU2007296843C1 (en)	2006-09-15	2012-08-16	Creabilis Therapeutics S.P.A.	Polymer conjugates of Box-A of HMGB1 and Box-A variants of HMGB1
EP2123299A4 (en) *	2007-02-15	2011-10-05	Univ Kyushu Nat Univ Corp	THERAPEUTIC AGENT FOR INTERSTITIAL PULMONARY DISEASE COMPRISING ANTI-HMGB-1 ANTIBODY
WO2008099913A1 (ja) *	2007-02-15	2008-08-21	Kumamoto University	ヒトhmgb-1に特異的に結合する抗体を有効成分として含有する治療剤
TW200846366A (en) *	2007-02-15	2008-12-01	Univ Fukuoka	Agent for suppressing rejection in organ transplantation comprising anti-hmgb-1 antibody
JP5660889B2 (ja)	2008-04-30	2015-01-28	株式会社ジェノミックス	末梢循環への骨髄由来多能性幹細胞動員薬
US9919010B2 (en)	2008-04-30	2018-03-20	Genomix Co., Ltd.	Method for collecting functional cells in vivo with high efficiency
JP5467313B2 (ja)	2009-09-28	2014-04-09	国立大学法人岡山大学	アテローム動脈硬化抑制剤
CN104825491A (zh)	2009-10-28	2015-08-12	吉诺米克斯股份有限公司	利用骨髓间充质干细胞和/或多能干细胞的血中动员的组织再生促进剂
US8956618B2 (en)	2010-01-21	2015-02-17	The Texas A&M University System	Vaccine vectors and methods of enhancing immune responses
NZ718006A (en)	2010-06-09	2017-06-30	Univ Arkansas	Vaccine and methods to reduce campylobacter infection
EP2613797B1 (en) *	2010-09-09	2015-11-04	University Of Southern California	Compositions and methods for the removal of biofilms
KR102113809B1 (ko)	2011-04-26	2020-05-21	가부시키가이샤 스템림	조직 재생을 유도하기 위한 펩티드 및 그의 이용
WO2012170740A2 (en) *	2011-06-07	2012-12-13	University Of Hawaii	Biomarker of asbestos exposure and mesothelioma
US9561274B2 (en)	2011-06-07	2017-02-07	University Of Hawaii	Treatment and prevention of cancer with HMGB1 antagonists
JP6253590B2 (ja) *	2012-10-25	2017-12-27	株式会社ジェノミックス	Ｈｍｇｂ１断片を利用した脊髄の損傷に対する新規治療法
PL2913058T3 (pl) *	2012-10-25	2018-04-30	Genomix Co., Ltd.	Nowy sposób leczenia zawału mięśnia sercowego przy użyciu fragmentu HMGB1
KR102228324B1 (ko)	2013-02-14	2021-03-15	더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소	에이메리아에 대한 면역 반응을 증진시키거나, 에이메리아 감염을 제한하는 조성물 및 방법
BR112015023024B1 (pt)	2013-03-15	2022-04-19	The Board Of Trustees Of The University Of Arkansas	Vetor de vacina e composições farmacêuticas compreendendo o mesmo
US11274144B2 (en)	2013-06-13	2022-03-15	Research Institute At Nationwide Children's Hospital	Compositions and methods for the removal of biofilms
US9745366B2 (en)	2013-09-23	2017-08-29	University Of Southern California	Compositions and methods for the prevention of microbial infections
US10233234B2 (en)	2014-01-13	2019-03-19	Trellis Bioscience, Llc	Binding moieties for biofilm remediation
US11248040B2 (en)	2013-09-26	2022-02-15	Trellis Bioscience, Llc	Binding moieties for biofilm remediation
GB201508337D0 (en)	2015-05-15	2015-06-24	Hmgbiotech S R L	Novel peptides
AU2016303688B2 (en)	2015-07-31	2023-06-15	Research Institute At Nationwide Children's Hospital	Peptides and antibodies for the removal of biofilms
CA3023144A1 (en)	2016-05-03	2017-11-09	The Board Of Trustees Of The University Of Arkansas	Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same
PL3556378T3 (pl)	2017-01-27	2025-06-09	StemRIM Inc.	Środek do leczenia kardiomiopatii, starego zawału mięśnia sercowego i przewlekłej niewydolności serca
AU2018236271B2 (en)	2017-03-15	2023-12-21	Research Institute At Nationwide Children's Hospital	Composition and methods for disruption of bacterial biofilms without accompanying inflammation
EP3719117A4 (en)	2017-12-01	2021-11-03	Stemrim Inc.	EECTODERMAL MESENCHYMAL STEM CELLS AND METHOD FOR PRODUCING THEM
US11298403B2 (en)	2017-12-01	2022-04-12	StemRIM Inc.	Therapeutic agent for inflammatory bowel disease
US20210024594A1 (en)	2018-02-08	2021-01-28	StemRIM Inc.	Therapeutic Agent for Psoriasis
CN112823038B (zh)	2018-10-05	2025-10-03	国家儿童医院研究所	用于移除生物膜的hmgb1蛋白衍生物
US12304933B2 (en)	2018-10-05	2025-05-20	StemRIM Inc.	Disease treatment drug based on mesenchymal-stem-cell mobilization
CN113203857B (zh) *	2021-05-06	2021-12-31	上海奕检医学检验实验室有限公司	一种肿瘤诊断试剂盒

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US144201A (en) *		1873-11-04		Improvement in volute springs
US60410A (en) *		1866-12-11		newman
US53841A (en) *		1866-04-10		Improvement in measuring-funnels
JPS62166897A (ja) *	1986-01-20	1987-07-23	Toyo Soda Mfg Co Ltd	核内非ヒストン蛋白質に対するモノクロ−ナル抗体
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
GB8823869D0 (en) *	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
US5605690A (en) *	1989-09-05	1997-02-25	Immunex Corporation	Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5545806A (en) *	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5656272A (en) *	1991-03-18	1997-08-12	New York University Medical Center	Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
GB9217316D0 (en) *	1992-08-14	1992-09-30	Ludwig Inst Cancer Res	Schwann cell mitogenic factor,its preparation and use
JP3472048B2 (ja) *	1995-10-09	2003-12-02	鐘淵化学工業株式会社	自己免疫疾患の診断薬
US6323329B1 (en) *	1995-12-21	2001-11-27	Jorn Bullerdiek	Nucleic acid sequences of genes encoding high mobility group proteins
US6171779B1 (en) *	1996-07-12	2001-01-09	University Of Medicine & Dentistry Of New Jersey	HMGI proteins in cancer
US6720472B2 (en) *	1996-07-12	2004-04-13	University Of Medicine And Dentistry Of New Jersey	HMGI proteins in cancer and obesity
AU719555B2 (en) *	1996-07-17	2000-05-11	Kaneka Corporation	Diagnostic drugs for autoimmune diseases
US20030032090A1 (en) *	1997-05-07	2003-02-13	Schering Corporation, A New Jersey Corporation	Human receptor proteins; related reagents and methods
US20030027260A1 (en) *	1997-10-17	2003-02-06	Genentech, Inc.	Human Toll homologues
US6228642B1 (en)	1998-10-05	2001-05-08	Isis Pharmaceuticals, Inc.	Antisense oligonucleotide modulation of tumor necrosis factor-(α) (TNF-α) expression
US6303321B1 (en) *	1999-02-11	2001-10-16	North Shore-Long Island Jewish Research Institute	Methods for diagnosing sepsis
US7151082B2 (en) *	1999-02-11	2006-12-19	The Feinstein Institute For Medical Research	Antagonists of HMG1 for treating inflammatory conditions
US6177077B1 (en) *	1999-02-24	2001-01-23	Edward L. Tobinick	TNT inhibitors for the treatment of neurological disorders
AU3395900A (en) *	1999-03-12	2000-10-04	Human Genome Sciences, Inc.	Human lung cancer associated gene sequences and polypeptides
US6677321B1 (en) *	1999-12-09	2004-01-13	Bruce Levin	Methods and compositions for treatment of inflammatory disease
US6436703B1 (en) *	2000-03-31	2002-08-20	Hyseq, Inc.	Nucleic acids and polypeptides
WO2002000677A1 (en) *	2000-06-07	2002-01-03	Human Genome Sciences, Inc.	Nucleic acids, proteins, and antibodies
ITMI20010562A1 (it) *	2001-03-16	2002-09-16	Marco E Bianchi	Inibitori o antagonisti della proteina hmg1 per il trattamento di disordini vascolari
US20030032674A1 (en) *	2001-08-13	2003-02-13	Hwang Daniel H.	Use of unsaturated fatty acids to treat severe inflammatory diseases
JP2003052763A (ja) *	2001-08-16	2003-02-25	Paramount Bed Co Ltd	ベッドにおける側柵

2002
- 2002-05-15 US US10/147,447 patent/US20030060410A1/en not_active Abandoned
- 2002-05-15 CN CNB028120388A patent/CN100447154C/zh not_active Expired - Fee Related
- 2002-05-15 IL IL15864302A patent/IL158643A0/xx unknown
- 2002-05-15 EP EP02736852A patent/EP1392844A4/en not_active Withdrawn
- 2002-05-15 AU AU2002309829A patent/AU2002309829B2/en not_active Ceased
- 2002-05-15 WO PCT/US2002/015329 patent/WO2002092004A2/en not_active Ceased
- 2002-05-15 CZ CZ20033402A patent/CZ20033402A3/cs unknown
- 2002-05-15 HU HU0500042A patent/HUP0500042A3/hu unknown
- 2002-05-15 MX MXPA03010449A patent/MXPA03010449A/es active IP Right Grant
- 2002-05-15 JP JP2002588923A patent/JP2005512507A/ja active Pending
- 2002-05-15 KR KR10-2003-7014914A patent/KR20040018370A/ko not_active Ceased
- 2002-05-15 BR BR0209689-7A patent/BR0209689A/pt not_active Application Discontinuation
- 2002-05-15 NZ NZ529423A patent/NZ529423A/en not_active IP Right Cessation
- 2002-05-15 PL PL02367132A patent/PL367132A1/xx not_active Application Discontinuation
- 2002-05-15 SK SK1542-2003A patent/SK15422003A3/sk unknown
- 2002-05-15 CA CA2447576A patent/CA2447576C/en not_active Expired - Fee Related
2003
- 2003-06-06 US US10/456,949 patent/US20040005316A1/en not_active Abandoned
- 2003-10-28 IL IL158643A patent/IL158643A/en not_active IP Right Cessation
- 2003-11-14 NO NO20035087A patent/NO20035087L/no not_active Application Discontinuation
- 2003-11-14 IS IS7037A patent/IS7037A/is unknown
2010
- 2010-10-24 IL IL208892A patent/IL208892A/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
EP1392844A2 (en)	2004-03-03
HUP0500042A2 (hu)	2005-03-29
EP1392844A4 (en)	2006-09-06
US20030060410A1 (en)	2003-03-27
WO2002092004A3 (en)	2003-10-09
CA2447576C (en)	2014-04-08
US20040005316A1 (en)	2004-01-08
CZ20033402A3 (cs)	2004-10-13
CN100447154C (zh)	2008-12-31
HUP0500042A3 (en)	2010-01-28
KR20040018370A (ko)	2004-03-03
PL367132A1 (en)	2005-02-21
AU2002309829B2 (en)	2007-08-23
IS7037A (is)	2003-11-14
WO2002092004A2 (en)	2002-11-21
CN1516739A (zh)	2004-07-28
IL158643A (en)	2010-12-30
SK15422003A3 (sk)	2005-01-03
NO20035087D0 (no)	2003-11-14
NO20035087L (no)	2003-12-09
NZ529423A (en)	2008-10-31
IL208892A (en)	2015-04-30
JP2005512507A (ja)	2005-05-12
CA2447576A1 (en)	2002-11-21
IL208892A0 (en)	2011-07-31
MXPA03010449A (es)	2004-12-06
WO2002092004A8 (en)	2003-11-27
IL158643A0 (en)	2004-05-12

Publication	Publication Date	Title
BR0209689A (pt)	2006-02-07	Uso de fragmento de hmg como agente anti-inflamatório
BR0112160A (pt)	2003-10-07	Agentes antiinflamatórios seletivos para glicocorticóides
BRPI0417684A (pt)	2007-03-20	composto, composição farmacêutica, e, uso de um composto
WO2004046345A3 (en)	2004-12-02	Use of hmgb fragments as anti-inflammatory agents
BRPI0411319A (pt)	2006-07-18	compostos terapeuticamente ativos e sua utilização
BR0211390A (pt)	2004-08-17	Tratamento de infecções da unha com no
BRPI0409879A (pt)	2006-05-16	composições e métodos para imunoterapia especìfica wt1
BRPI0413028A (pt)	2006-10-03	composto, uso de um composto, composição farmacêutica, e, kit farmacêutico
BR0206985A (pt)	2005-04-19	Anticorpos modificados e métodos de uso
TR200103233T2 (tr)	2002-04-22	Antikolinerjik etkili bileşik ve ß-mimetikler bazında yeni ilaç bileşimleri.
BR0209177A (pt)	2004-10-05	Anticorpo especìfico a tumor recombinante e uso do mesmo
BR0007487A (pt)	2003-09-23	Difenil-uréias substituìdas com w-carbóxi-arilas como inibidores de raf cinase
BRPI0416700A (pt)	2007-03-06	métodos para tratar obesidade, para alcançar perda de peso desejável, para evitar ganho de peso indesejável, e para facilitar a perda de peso em um indivìduo não sofrendo de depressão, métodos de manutenção de um peso estável e de redução do peso corporal em um indivìduo, composição farmacêutica, e, kit
BR0210056A (pt)	2006-04-04	composições e métodos para tratamento de hiperplasia
BR112022016456A2 (pt)	2022-10-04	Formulações de anticorpos anti-tslp humanos e métodos de uso dos mesmos
ATE272628T1 (de)	2004-08-15	Substituierte gamma-phenyl-delta-lactone und deren analoge, und ihre verwendungen
DE60040753D1 (de)	2008-12-18	Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden
TR199802769T2 (xx)	1999-04-21	Terpenoid bileşikler ile antihistaminik bileşiklerin bir kombinasyonunu ihtiva eden topikal bileşim.
EP1423137A4 (en)	2005-11-30	Lipopeptide stereoisomers, methods for preparing same, and useful intermediates
WO1999045098A3 (en)	1999-12-23	Delivery or proteins into eukaryotic cells with recombinant yersinia
BRPI0409742A (pt)	2006-05-09	uso de um agente anti-angiogênico, em combinação com um inibidor da famìlia src de tirosina quinases não-receptoras, produto de combinação, e, composição farmacêutica
BR0008302A (pt)	2002-08-27	Uso de um derivado de benzaldeìdo, derivado de benzaldeìdo, composição farmacêutica, e, processo para a fabricação da mesma
BR0109846A (pt)	2003-06-03	Uso de uma composição que compreende um anticorpo ou um fragmento de ligação de antìgeno deste, e conjunto
BR0306732A (pt)	2004-12-28	Tratamentos em combinação para doença alérgica compreendendo a administração de um anticorpo anti-ige e composto antialérgico
BR0314716A (pt)	2005-07-26	Anticorpos de subunidade alfa de lfa-1 e métodos de uso

Legal Events

Date	Code	Title	Description
2011-04-19	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2013-05-07	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2013-12-17	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2013-12-24	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2014-09-02	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2015-03-17	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2015-07-28	B09B	Patent application refused [chapter 9.2 patent gazette]	Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O C/C 11, 8O C/C 13, 10, 24 E 25 DA LPI.
2015-10-27	B09B	Patent application refused [chapter 9.2 patent gazette]	Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.
2015-11-17	B25D	Requested change of name of applicant approved	Owner name: THE GENERAL HOSPITAL CORPORATION (US) , UNIVERSITY